Journal of Chest Surgery

The Korean Society for Thoracic and Cardiovascular Surgery (대한심장혈관흉부외과학회)
권호 표지

Effects of Preoperative Continuous Use of Aspirin and Plavix in off-pump Coronary Artery Bypass Surgery

아스피린과 플라빅스의 수술 전 지속적 사용이 무심폐기 하 관상동맥우회술에 미치는 영향

  • Yi Gijong (Department of Thoracic and Cardiovascular Surgery, Yongdong Severance Hospital, Yonsei University College of Medicine) ;
  • Lee Kyo-Joon (Department of Thoracic and Cardiovascular Surgery, Yongdong Severance Hospital, Yonsei University College of Medicine) ;
  • Yang Hong-Seok (Department of Thoracic and Cardiovascular Surgery, Yongdong Severance Hospital, Yonsei University College of Medicine) ;
  • Ahn Ji-Young (Department of Thoracic and Cardiovascular Surgery, Yongdong Severance Hospital, Yonsei University College of Medicine) ;
  • Yoo Kyung-Jong (Department of Thoracic and Cardiovascular Surgery, Yongdong Severance Hospital, Yonsei University College of Medicine)
  • 이기종 (연세대학교 의과대학 흉부외과학교실, 영동세브란스병원) ;
  • 이교준 (연세대학교 의과대학 흉부외과학교실, 영동세브란스병원) ;
  • 양홍석 (연세대학교 의과대학 흉부외과학교실, 영동세브란스병원) ;
  • 안지영 (연세대학교 의과대학 흉부외과학교실, 영동세브란스병원) ;
  • 유경종 (연세대학교 의과대학 흉부외과학교실, 영동세브란스병원)
  • Published : 2006.01.01
Download PDF
⟨ Previous Next ⟩

Abstract

Background: The benefits of preoperative use of aspirin and plavix in coronary patients have been well documented. Due to their bleeding tendency, there have been many discussions about when to stop the antiplatelet agent before operation. We evaluated the effects of preoperative continuous use of aspirin and plavix in OPCAB patients. Material and Method: 123 patients underwent OPCAB from March, 2004 to Feb., 2005. We divided them into two groups; those who had continuous administration of aspirin and plavix during the preoperative period (n=45, 36.6$\%$) and those who discontinued them at least one day before the operation (n=78, 63.4$\%$). We then compared the platelet count, hemoglobin/hematocrit level, graft patency, postoperative bleeding and related complications, and operation time between the two groups. The patients were also divided into long-term users ($\geq$ 1 month) and short-term users (< 1 month), with the aforementioned factors equally compared. Result: There was no statistical difference between the two groups regarding postoperative bleeding, related complications, graft patency, operation time and mortality. Continuous users showed significantly low platelet levels on immediate post operation (p=0.02), postoperative day (POD) $\sharp$1 (p=0.002) and POD $\sharp$2 (p=0.021), respectively. But there was no difference on POD $\sharp$7. Long-term users showed statistically significant difference in pre- and postoperative platelet count, but none in postoperative bleeding and related complications. Conclusion: Continuous use of aspirin and plavix did not increase postoperative bleeding or related complications. Also graft patency and mortality had no statistical differences in continuous users. We think that there is no need to stop aspirin and plavix before OPCAB.

배경: 아스피린과 플라빅스는 관상동맥 환자들에게 가장 흔히 사용하는 항혈소판 제제이나 수술 후 출혈 성향의 증가에 대한 우려 때문에 수술 5일에서 7일 전에 복용을 중단하는 것이 일반적이다. 본 연구에서는 이들 약제들의 지속적 사용이 무심폐기 하 관상동맥우회 술(Off pump coronary artery bypass grafting, Off pump CABG) 후의 결과에 어떤 영향을 미치는지에 관하여 조사하였다. 대상 및 방법: 2004년 3월부터 2005년 2월까지 Off pump CABG를 시행 받은 123명의 환자들을 대상으로 하여 수술 전후에 아스피린과 플라빅스를 끊지 않고 지속적으로 사용한 군(n=45, 36.6$\%$)과 적어도 수술 1일 이전에 끊은 군(n=78, 63.4$\%$) 사이에 수술 전후 혈소판, 헤모글로빈/헤마토크리트 수치, 수술 후 출혈량, 도관 개통률, 수술 시간 등을 비교하였다. 또한 대상환자들을 수술 전에 아스피린을 1달 이상 사용했던 장기 사용군과 그렇지 않은 군으로 구분하여 상기 요소들을 비교하였다. 결과: 수술에 의한 사망은 없었으며 출혈에 관한 합병증으로는 출혈에 의한 재수술과 상부 소화관 출혈이 각각 1예씩 있었다. 지속적으로 사용한 군과 그렇지 않은 군의 비교에 있어서는 수술 직후와 수술 후 1, 2일의 혈소판 수치가 지속적 사용군에서 유의하게 낮았으나(p=0.02, p=0.002, p=0.021) 수술 후 출혈량, 수혈 빈도, 출혈 관련 합병증 및 도관의 개통률에는 차이가 없었다 아스피린을 1달 이상 사용한 장기 사용군의 경우 그렇지 않은 군에 비하여 수술 전후의 혈소판 수치가 지속적으로 낮았으나 출혈량, 수혈 빈도, 합병증 및 도관의 개통률에는 차이가 없었다. 결론: 아스피린과 플라빅스의 Off pump CABG 전후의 지속적 사용은 수술 후 일시적인 혈소판 수치의 감소를 초래할 수 있으나 수술 후 출혈량, 수혈 여부, 수술 시간, 출혈과 관련된 합병증 및 도관의 개통률에는 영향을 주지 않았다. 그러므로 Off pump CABG에 있어서 아스피린과 플라빅스는 수술 전까지 지속적으로 사용하여도 될 것으로 생각한다.

Keywords

References

  1. Gum PA, Thamilarasan M, Watanabe J, Blackstone EH, Lauer MS. Aspirin use and all-cause mortality among patients being evaluated for known or suspected coronary artery disease: a propensity analysis. JAMA 2001;286:1187-94 https://doi.org/10.1001/jama.286.10.1187
  2. Fuster V, Cohen M, Halperin J. Aspirin in the prevention of coronary disease. N Engl J Med 1989;321:183-5 https://doi.org/10.1056/NEJM198907203210308
  3. Goldman S, Copeland J, Moritz T, et al. Improvement in early saphenous vein graft patency after coronary artery bypass surgery with antiplatelet therapy: results of a Veterans Administration Cooperative Study. Circulation 1988;77:1324- 32 https://doi.org/10.1161/01.CIR.77.6.1324
  4. Chesebro JH, Clements IP, Fuster V, et al. A platelet inhibitor drug trial in coronary artery bypass operations: benefit of perioperative dipyridamole and aspirin therapy on early post-operative vein graft patency. N Engl J Med 1982;307: 73-8 https://doi.org/10.1056/NEJM198207083070201
  5. Gavaghan TP, Gebski V, Baron DW. Immediate postoperative aspirin improves vein graft patency early and late after coronary artery bypass graft surgery. Circulation 1991;83: 1526-33 https://doi.org/10.1161/01.CIR.83.5.1526
  6. Dacey LJ, Munoz JJ, Johnson ER, Leavitt BJ, Maloney CT, Morton JR. Effect of preoperative aspirin use on mortality in coronary artery bypass grafting patients. Ann Thorac Surg 2000;70:1986-90 https://doi.org/10.1016/S0003-4975(00)02133-0
  7. Williams A, Hennekens CH. The role of aspirin in cardiovascular diseases-forgotten benefits? Expert Opin Pharmacother 2004;5:109-15 https://doi.org/10.1517/14656566.5.1.109
  8. Chu MW, Wilson SR, Novick RJ, Stitt LW. Does clopidogrel increase blood loss following coronary artery bypass surgery? Ann Thorac Surg 2004;78:1536-40 https://doi.org/10.1016/j.athoracsur.2004.03.028
  9. Srinivasan AK, Grayson AD, Pullan DM, Fabri BM, Dihmis WC. Effect of preoperative aspirin use in off-pump coronary artery bypass operations. Ann Thorac Surg 2003;76:41-5 https://doi.org/10.1016/S0003-4975(03)00182-6
  10. Englberger L, Faeh B, Berdat PA, Eberli F, Meier B, Carrel T. Impact of clopidogrel in coronary artery bypass grafting. Eur J Cardiothorac Surg 2004;26:96-101 https://doi.org/10.1016/j.ejcts.2004.03.030
  11. Belisle S, Hardy JF. Hemorrhage and the use of blood products after adult cardiac operations: myths and realities. Ann Thorac Surg 1996;62:1908-17 https://doi.org/10.1016/S0003-4975(96)00944-7
  12. Sethi GK, Copeland JG, Goldman S, Moritz T, Azdina K, Henderson WG. Implication of preoperative aspirin in patients undergoing coronary artery bypass grafting. J Am Coll Cardiol 1990;15:15-20 https://doi.org/10.1016/0735-1097(90)90168-O
  13. Karthik S, Grayson AD, McCarron EE, Pullan DM, Desmond MJ. Reexploration for bleeding after coronary artery bypass surgery: risk factors, outcomes, and the effect of time delay. Ann Thorac Surg 2004;78:527-34 https://doi.org/10.1016/j.athoracsur.2004.02.088
  14. Ferraris VA, Ferraris SP, Moliterno DJ, Camp P, Walenga JM, Messmore HL. The society of thoracic surgeons practice guideline series: aspirin and other antiplatelet agents during operative coronary revascularization (executive summary). Ann Thorac Surg 2005;79:1454-61 https://doi.org/10.1016/j.athoracsur.2005.01.008
  15. Hongo RH, Ley J, Dick SE, Yee RR. The effect of clopidogrel in combination with aspirin when given before coronary artery bypass grafting. J Am Coll Cardiol 2002;40:231-7 https://doi.org/10.1016/S0735-1097(02)01954-X
  16. Yende S, Wunderink R. Effect of clopidogrel on bleeding after coronary artery bypass surgery. Crit Care Med 2001; 29:2271-5 https://doi.org/10.1097/00003246-200112000-00006
  17. Ascione R, Ghosh A, Rogers CA, Cohen A, Monk C, Angelini GD. In-hospital patients exposed to clopidogrel before coronary artery bypass graft surgery: a word of caution. Ann Thorac Surg 2005;79:1210-6 https://doi.org/10.1016/j.athoracsur.2004.09.046
  18. D'Ancona G, Donias HW, Karamanoukian RL, Bergsland J, Karamanoukian HL. OPCAB therapy survey: off-pump clopidogrel, aspirin or both therapy survey. Heart Surg Forum 2001;4:354-8
  19. Yoo KJ, Choi DH, Choi BW, Lim SH, Chang BC. The comparison of the graft patency after coronary artery bypass grafting using coronary angiography and multi-slice computed tomography. Eur J Cardiothorac Surg 2003;24:86-91 https://doi.org/10.1016/S1010-7940(03)00192-1
  20. Chiurlia E, Menozzi M, Ratti C, Romagnoli R, Modena MG. Follow-up of coronary artery bypass graft patency by multislice computed tomography. Am J Cardiol 2005;95:1094-7 https://doi.org/10.1016/j.amjcard.2004.12.067
  21. Englberger L, Markart P, Eckstein FS, Immer FF, Berdat PA, Carrel TP. Aprotinin reduces blood loss in off-pump coronary artery bypass surgery. Eur J Cardiothorac Surg 2002; 22:545-51 https://doi.org/10.1016/S1010-7940(02)00433-5
  22. Alvarez JM, Jackson LR, Chatwin C, Smolich JJ. Low-dose postoperative aprotinin reduces mediastinal drainage and blood product use in patients undergoing primary coronary artery bypass grafting who are taking aspirin: a prospective, randomized, double-blind, placebo-controlled trial. J Thorac Cardiovasc Surg 2001;122:457-63 https://doi.org/10.1067/mtc.2001.115701
  23. Bidstrup BP, Hunt BJ, Sheikh S, Parratt RN, Bidstrup JM, Sapsford RN. Amelioration of the bleeding tendency of preoperative aspirin after aortocoronary bypass grafting. Ann Thorac Surg 2000;69:541-7 https://doi.org/10.1016/S0003-4975(99)01337-5
  24. Poston R, Gu J, Manchio J, Lee A, Brown J, Gammie J. Platelet function tests predict bleeding and thrombotic events after off-pump coronary bypass grafting. Eur J Cardiothorac Surg 2005;27:584-91 https://doi.org/10.1016/j.ejcts.2004.12.061
  25. Furukawa K, Ohteki H. Changes in platelet aggregation after suspension of aspirin therapy. J Thorac Cardiovasc Surg 2004;127:1814-5 https://doi.org/10.1016/j.jtcvs.2003.12.025